4.6 Review

Biochemical markers in early diagnosis and management of systemic amyloidoses

Journal

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 52, Issue 11, Pages 1517-1531

Publisher

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2014-0235

Keywords

amyloidosis; biomarkers; early diagnosis; monoclonal gammopathies

Funding

  1. Associazione Italiana per la Ricerca sul Cancro, special program '5 per mille' [9965]
  2. Italian Ministry of Health [GR-2010-2317596]
  3. Fondazione Cariplo [2013-0964]
  4. Amyloid Foundation and Fondazione Mintas, Ghislieri College, Pavia

Ask authors/readers for more resources

Systemic amyloid diseases are characterized by widespread protein deposition as amyloid fibrils. Precise diagnostic framing is the prerequisite for a correct management of patients. This complex process is achieved through a series of steps, which include detection of the tissue amyloid deposits, identification of the amyloid type, demonstration of the amyloidogenic precursor, and evaluation of organ dysfunction/damage. Laboratory medicine plays a central role in the diagnosis and management of systemic amyloidoses, through the quantification of the amyloidogenic precursor and evaluation of end-organ damage using biomarkers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available